<DOC>
	<DOC>NCT00642161</DOC>
	<brief_summary>A comparison of the safety, efficacy and budesonide pharmacokinetics of the currently approved Pulmicort Turbuhaler with a new version of the inhaler, in children and adolescents who have asthma. In addition the study evaluated the functionality of the new inhaler at the end of its intended life.</brief_summary>
	<brief_title>New Version Pulmicort Turbuhaler USA Children</brief_title>
	<detailed_description />
	<mesh_term>Budesonide</mesh_term>
	<criteria>Male or females aged 6 to 17 with a diagnosis of asthma for at least 3 months. Have used inhaled corticosteroids for no more than one month before entering the study or none at all. A forced expiratory volume (FEV1) in 1 second of 75% to 90% of predicted normal for those aged 6 to 11 and 60% to 90% for those aged 12 to 17 years. Airway reversibility of at least 12% , use of orally inhaled corticosteroids for no more than one month immediately before entering the study or none at all. Life threatening asthma, Two or more overnight hospitalisations for asthma within 1 year or any emergency room visit for asthma within 6 months of starting study. Use of steroid tablets or injections during the month prior to Visit 1 and use of other asthma medicines (except rescue medication) within 2 weeks prior to the study. Any acute exacerbation of asthma or a respiratory tract infection within 30 days prior to Visit 1. Must not smoke or have smoked.</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Pulmicort</keyword>
	<keyword>Children</keyword>
	<keyword>Paediatrics</keyword>
	<keyword>budesonide</keyword>
	<keyword>Flexhaler</keyword>
</DOC>